Predicting response to neoadjuvant treatment in rectal cancer is crucial for tailoring treatment. While tumor-infiltrating lymphocytes (TILs) have been suggested as predictors, results are inconsistent. This study aimed to refine prediction using multiplex immunofluorescence (mIF) on pre-operative biopsies, combining conventional T cell subsets, γδT cells, and a type I interferon (IFN) response (assessed by Myxovirus resistance protein A (MxA) expression). Pathological complete response (pCR) was associated with type I IFN. Stratifying patients based on CD8+ T cell density and MxA+ cell density improved prediction compared to the biopsy-adapted Immunoscore (IS B). This novel approach using these two independent parameters could help identify patients likely to achieve pCR after neoadjuvant treatment.
Publisher
Oncoimmunology
Published On
May 01, 2023
Authors
Azar Rezapour, Daniel Rydbeck, Fabian Byvald, Viktor Tasselius, Gustaf Danielsson, Eva Angenete, Ulf Yrlid
Tags
rectal cancer
neoadjuvant treatment
tumor-infiltrating lymphocytes
multiplex immunofluorescence
type I interferon
pathological complete response
CD8+ T cells
Related Publications
Explore these studies to deepen your understanding of the subject.
